Edition:
United States

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.19USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.19
Open
$1.19
Day's High
$1.19
Day's Low
$1.18
Volume
6,810
Avg. Vol
39,761
52-wk High
$3.06
52-wk Low
$1.07

Chart for

About

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $18.82
Shares Outstanding(Mil.): 15.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.98 16.31
EPS (TTM): -- -- --
ROI: -- 14.12 35.74
ROE: -- 15.72 17.71

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

Feb 07 2018

BRIEF-Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions

* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING

Jan 08 2018

BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131

* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131

Dec 06 2017

BRIEF-Cellectar Biosciences posts Q3 loss of $0.26 per share

* Cellectar Biosciences reports third quarter 2017 financial and corporate performance

Nov 09 2017

BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma

* Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Cellectar Biosciences announces new preclinical data

* ‍New preclinical data suggest that Cellectar Biosciences' PDC platform provides enhanced outcomes in combination with external radiation​

Oct 30 2017

BRIEF-Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan

* Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors

Oct 17 2017

BRIEF-Cellectar Biosciences and Pierre Fabre extend collaboration

* Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates

Oct 10 2017

BRIEF-Cellectar Biosciences reports partial response in a relapsed or refractory multiple myeloma patient treated with CLR 131

* Cellectar Biosciences reports cohort four data and partial response in relapsed or refractory multiple myeloma patient treated with CLR 131

Sep 27 2017

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

Sep 21 2017

Competitors

Earnings vs. Estimates